Febantel
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Febantel
- DrugBank Accession Number
- DB11409
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental, Vet approved
- Structure
- Weight
- Average: 446.48
Monoisotopic: 446.126005618 - Chemical Formula
- C20H22N4O6S
- Synonyms
- Febantel
- Febantelum
- External IDs
- BAY H 5757
- BAY VH 5757
- BAY Vh5757
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- Negabot Plus Paste / Oratel / Rintal
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as diarylthioethers. These are organosulfur compounds containing a thioether group that is substituted by two aryl groups.
- Kingdom
- Organic compounds
- Super Class
- Organosulfur compounds
- Class
- Thioethers
- Sub Class
- Aryl thioethers
- Direct Parent
- Diarylthioethers
- Alternative Parents
- Anilides / Thiophenol ethers / N-arylamides / Methylcarbamates / Guanidines / Secondary carboxylic acid amides / Organic carbonic acids and derivatives / Propargyl-type 1,3-dipolar organic compounds / Sulfenyl compounds / Dialkyl ethers show 6 more
- Substituents
- Anilide / Aromatic homomonocyclic compound / Benzenoid / Carbamic acid ester / Carbonic acid derivative / Carbonyl group / Carboxamide group / Carboximidamide / Carboxylic acid derivative / Dialkyl ether show 19 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- S75C401OS1
- CAS number
- 58306-30-2
- InChI Key
- HMCCXLBXIJMERM-UHFFFAOYSA-N
- InChI
- InChI=1S/C20H22N4O6S/c1-28-12-17(25)21-16-11-14(31-13-7-5-4-6-8-13)9-10-15(16)22-18(23-19(26)29-2)24-20(27)30-3/h4-11H,12H2,1-3H3,(H,21,25)(H2,22,23,24,26,27)
- IUPAC Name
- methyl N-{[(methoxycarbonyl)amino]({[2-(2-methoxyacetamido)-4-(phenylsulfanyl)phenyl]imino})methyl}carbamate
- SMILES
- COCC(=O)NC1=C(C=CC(SC2=CC=CC=C2)=C1)N=C(NC(=O)OC)NC(=O)OC
References
- General References
- Thomas H: Ovacidal activity of febantel. N Z Vet J. 1979 Dec;27(12):273-5. [Article]
- Ben-Zvi Z, Gussarsky E, van Creveld C, Yagil R: The bioavailability of febantel in dehydrated camels. J Vet Pharmacol Ther. 1996 Aug;19(4):288-94. [Article]
- Wollweber H, Kolling H, Widdig A, Thomas H, Schulz HP, Murmann P: Febantel, a new broad-spectrum anthelminthic. Arzneimittelforschung. 1978;28(12):2193-5. [Article]
- Blagburn BL, Hendrix CM, Hanrahan LA, Lindsay DS, Arther RG, Drane JW: Controlled dosage titration of febantel paste in naturally parasitized cattle. Am J Vet Res. 1989 Sep;50(9):1574-7. [Article]
- Corwin RM, Pratt SE, McCurdy HD: Anthelmintic effect of febantel/praziquantel paste in dogs and cats. Am J Vet Res. 1984 Jan;45(1):154-5. [Article]
- Stuedemann JA, Ciordia H, Arther RG: Anthelmintic efficacy of febantel paste in naturally infected calves. Vet Parasitol. 1990 Apr;35(4):341-7. [Article]
- Sharp ML, McCurdy HD: Anthelmintic efficacy of febantel combined with praziquantel in dogs. J Am Vet Med Assoc. 1985 Aug 1;187(3):254-5. [Article]
- Williams JC, Marbury KS, Eddi CS, Willis ER, Luther DG: Efficacy of febantel against abomasal nematodes and lungworms in cattle. Am J Vet Res. 1988 Dec;49(12):2085-9. [Article]
- Ciordia H, McCampbell HC, Stuedemann JA: Anthelmintic efficacy of febantel against gastrointestinal helminths in calves. Am J Vet Res. 1982 Dec;43(12):2248-9. [Article]
- Hagan CJ: More on febantel and trichlorfon. Vet Med Small Anim Clin. 1979 Jan;74(1):6. [Article]
- External Links
- KEGG Drug
- D04135
- ChemSpider
- 4514715
- BindingDB
- 50103610
- 24805
- ChEMBL
- CHEMBL1080983
- ZINC
- ZINC000004215999
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0052 mg/mL ALOGPS logP 2.73 ALOGPS logP 3.17 Chemaxon logS -4.9 ALOGPS pKa (Strongest Acidic) 9.48 Chemaxon pKa (Strongest Basic) -2.6 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 127.35 Å2 Chemaxon Rotatable Bond Count 8 Chemaxon Refractivity 118.27 m3·mol-1 Chemaxon Polarizability 45.85 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-000j-0009600000-09e429115c37873a1be8 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-05o0-0009000000-985f8849bd1f31744c32 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-000x-7009000000-4b3af3877c8f21db31c9 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-00ts-0029800000-fd0fdc2b617a8afbe672 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-001i-0009000000-838171dc2f6b223880dd Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0076-0029000000-27da69adee9451b51846 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 219.8703932 predictedDarkChem Lite v0.1.0 [M-H]- 198.49715 predictedDeepCCS 1.0 (2019) [M+H]+ 219.1999932 predictedDarkChem Lite v0.1.0 [M+H]+ 200.85515 predictedDeepCCS 1.0 (2019) [M+Na]+ 218.3324932 predictedDarkChem Lite v0.1.0 [M+Na]+ 207.09544 predictedDeepCCS 1.0 (2019)
Drug created at February 25, 2016 18:28 / Updated at February 21, 2021 18:53